---
title: "What is Zacks Research's Forecast for BIO FY2026 Earnings?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258502627.md"
description: "Zacks Research has lowered its FY2026 earnings per share (EPS) estimate for Bio-Rad Laboratories (NYSE:BIO) from $10.43 to $10.36. The current consensus estimate for the company's full-year earnings is $10.81 per share. Zacks maintains a \"Hold\" rating on the stock, while Wells Fargo and Royal Bank of Canada have increased their price targets. Bio-Rad's stock opened at $283.63, with a market cap of $7.68 billion and a PE ratio of 24.18. Recent quarterly earnings exceeded expectations, reporting $2.61 EPS against a consensus of $1.93."
datetime: "2025-09-23T10:45:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258502627.md)
  - [en](https://longbridge.com/en/news/258502627.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258502627.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/258502627.md) | [繁體中文](https://longbridge.com/zh-HK/news/258502627.md)


# What is Zacks Research's Forecast for BIO FY2026 Earnings?

-   The Top 3 Medical Devices Stocks to Buy Now

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Zacks Research decreased their FY2026 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a report released on Monday, September 22nd. Zacks Research analyst Team now anticipates that the medical research company will post earnings per share of $10.36 for the year, down from their previous forecast of $10.43. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q4 2026 earnings at $2.62 EPS.

Get **Bio-Rad Laboratories** alerts:

BIO has been the topic of several other research reports. Wells Fargo & Company upped their price target on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Royal Bank Of Canada upped their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a research note on Friday, August 1st. Finally, Wall Street Zen cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Friday, August 22nd. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $333.50.

**Read Our Latest Stock Report on BIO**

## Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $283.63 on Tuesday. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $387.99. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $7.68 billion, a PE ratio of 24.18 and a beta of 0.95. The firm's 50 day simple moving average is $275.86 and its 200 day simple moving average is $252.83.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.68. The firm had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $3.11 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.

## Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Nuveen Asset Management LLC boosted its position in Bio-Rad Laboratories by 0.8% during the 4th quarter. Nuveen Asset Management LLC now owns 39,505 shares of the medical research company's stock valued at $12,978,000 after buying an additional 327 shares during the period. ProShare Advisors LLC raised its stake in shares of Bio-Rad Laboratories by 8.0% during the fourth quarter. ProShare Advisors LLC now owns 901 shares of the medical research company's stock valued at $296,000 after acquiring an additional 67 shares during the last quarter. Tidal Investments LLC raised its stake in shares of Bio-Rad Laboratories by 21.1% during the fourth quarter. Tidal Investments LLC now owns 1,069 shares of the medical research company's stock valued at $351,000 after acquiring an additional 186 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Bio-Rad Laboratories by 70.3% during the fourth quarter. Two Sigma Investments LP now owns 2,050 shares of the medical research company's stock worth $673,000 after purchasing an additional 846 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $2,211,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

## About Bio-Rad Laboratories

(Get Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

## Read More

-   Five stocks we like better than Bio-Rad Laboratories
-   How to Invest in the FAANG Stocks
-   How The Weak Dollar Is Fueling These Global Stock Surges
-   How to Calculate Options Profits
-   3 Recession-Ready Stocks That Thrive When the Economy Sputters
-   Best Stocks Under $10.00
-   3 Automation-Focused Stocks Flying Under the Radar

_This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com._

## Should You Invest $1,000 in Bio-Rad Laboratories Right Now?

Before you consider Bio-Rad Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.

While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [Bio-Rad Laboratories, Inc. (BIO.US)](https://longbridge.com/en/quote/BIO.US.md)

## Related News & Research

- [Assessing Bio-Rad (BIO) Valuation After Recent Share Price Weakness And Longer-Term Return Pressures](https://longbridge.com/en/news/275997412.md)
- [Bio-Rad Q4 revenue slightly beats estimates, helped by growth in Clinical Diagnostics unit](https://longbridge.com/en/news/275809784.md)
- [Pharma-Bio Serv Announces Full Year Results and Special Dividend | PBSV Stock News](https://longbridge.com/en/news/274214281.md)
- [Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference | BIO Stock News](https://longbridge.com/en/news/271659628.md)
- [Rockwell Automation, Laboratorios Farmacéuticos Rovi and Adasoft Implement Digital Batch Execution System](https://longbridge.com/en/news/278868159.md)